Skip to main content
. 2014 Sep 17;2014:265840. doi: 10.1155/2014/265840

Figure 1.

Figure 1

Effect of lenalidomide on the proliferation of B cells. (a) PBMCs obtained from healthy donors (n = 10) and CLL patients (n = 17) were labeled with CFSE and cultured with 1 μM lenalidomide or DMSO for 14 days. CFSE fluorescence in B cells (gated as CD5+/CD19+) was analyzed by flow cytometry. The histograms show a representative CLL patient and a healthy donor. (b) The figure shows the compilation of the results obtained from healthy donors and CLL patients. Results are expressed as the fold induction of the percentage of proliferating B cells in lenalidomide-treated cells relative to the vehicle-treated control (**P < 0.01, Mann-Whitney U test).